The ASX is expected to open lower on Friday after Wall Street ended its day red, with Tesla stock falling nearly 10 per cent.

Elon Musk announced price cuts to his Teslas in a bid to drive up demand, but it could come at a cost to the giant’s balance sheet.

Nonetheless, here on some stocks to keep an eye on during Friday’s trade:

Invex Therapeutics (IXC) has received regulatory approval in France to begin its IIH EVOLVE phase three trial for patients with Idiopathic Intracranial Hypertension (IIH).

The company also received an approved application to the Ethics Committee CPP.

“This approval from the ANSM/CPP in France completes our competent authority strategy in Europe, where IIH patients across Germany and France will be participating in this important Phase III clinical trial,” Invex Executive Director and Chief Scientific Officer Professor Alex Sinclair said.

Shares in IXC last traded at 44 cents.

Equatorial Resources (EQX) has entered an agreement to acquire the Nimab Alliance iron ore project in Guinea, West Africa.

The company said the acquisition aligned with its focus on the large-scale exploration and development of iron ore assets.

The Nimab Alliance project has one of the largest landholdings in Guinea’s prolific Nimaba Iron Ore Corridor.

Shares in EQX last traded at 14 cents.

Meanwhile, Macro Metals (M4M) has reported “high-grade” rock chip samples of up to 33 per cent copper from four samples taken during an initial site trip to the Mogul VMS project in Western Australia.

The company confirmed the results were consistent with rock chip samples of up to 36 per cent copper and 11 per cent zinc reported by previous operators.

Macro Metals has now called on induced polarisation (IP) and gravity geophysical contractors to define the extent of the “highly prospective” target.

Shares in M4M last traded at 0.5 cents.

Piedmont Lithium (PLL) has completed a definitive feasibility study (DFS) of the company’s proposed Tennessee lithium project in the United States.

The study uncovered robust project economics and the positive impact of America’s Inflation Reduct Act.

Piedmont President and CEO Keith Phillips said the project was “positioned to be a key resource for EV and battery manufacturers”.

Shares in PLL last traded at 84 cents.

Torque Metals (TOR) has uncovered multiple mineralised zones at its Paris project in Western Australia.

A recently-completed diamond drill program intersected highly altered fault zones, with sulphides and quartz veining over 30 metres in one hole and 32 and 23 metres in other holes, with assays pending.

The company also commenced a 43-hole reverse circulation (RC) drilling program for 5000 metres on Friday, including extensional and in-fill drilling at its Observation, Paris and HHH prospects.

Shares in TOR last traded at 14 cents.

ON Semiconductor Corporation (ON), a Semiconductors corporation, was a active mover in the prior market session. ON Semiconductor Corporation (ON) shares started the day for trading at $15.70 and closed the day at $14.95 with declining move of -4.53%. This decrease move lagged the S&P 500’s -2.05% lose on the prior market day.

ON Semiconductor Corporation (ON) is focused on the Semiconductors sector. This stock market sector has seen some volatility from day traders in recent months. Bullish day traders of ON Semiconductor Corporation (ON) will be looking for positive upcoming earnings whereas bearish day traders of ON Semiconductor Corporation (ON) will be looking for negative earnings. The last time ON Semiconductor Corporation (ON) had an earnings surprise was on Qtr Ending 03/20 when they reported $0.10 compared to an estimate of $0.15 which was a difference of -$0.05 resulting in a change of -33.33%. Current earnings estimates are to be released for Current Qtr 06/2020 on ON Semiconductor Corporation (ON) and out of 10 Wall Street estimates the average is saying $0.17. The high estimate is saying $0.28 whereas the low estimate is saying $0.01 and the prior year ON Semiconductor Corporation (ON) announced earnings at $0.42 a growth rate est. (year over year) of -59.52%.

The market performance of ON Semiconductor Corporation (ON) has varied recently. Year to date ON Semiconductor Corporation (ON)’s shares are down -35.77%. Over the past 12 weeks ON Semiconductor Corporation (ON) is down -26.96% and over the last 4 weeks ON Semiconductor Corporation (ON) is up 10.20%. ON Semiconductor Corporation (ON) current income statement shows revenue (ttm) of $5.52B. Gross Profit is $1.99B. This puts the current EBITDA of ON Semiconductor Corporation (ON) at $1.23B.

Wall street day traders might also notice recent changes to stock analyst estimates for ON Semiconductor Corporation (ON). The stock is trading with an RSI (relative strength index) of 50.02 indicating ON Semiconductor Corporation (ON) is neither overbought nor oversold. Technically, ON’s short term support levels are around $14.51, $13.98 and $13.01 on the downside. ONs short term resistance levels are $23.50, $22.70 and $22.24 on the upside. The market cap of ON Semiconductor Corporation (ON) is $6.121B and institutions hold 103.53% of the stock. The outstanding share count stands at 410.60M while the short float (shares short) stands at 5.52%.

Market research shows that these earning estimate changes look to be directly correlated with short-term shares prices. The day traders can look to capitalize on the basis of ranking. Based on technical analysis, ON has short term rating of Neutral (0.23), Intermediate rating of Neutral (0.23) and the long-term rating of Neutral (0.03) giving it an overall rating of Neutral (0.16).

The EPS growth this year on ON Semiconductor Corporation (ON) is decreased -61.70% and is expected to increase 66.22% next year. However, quarterly earnings (EPS) growth year over year on ON Semiconductor Corporation (ON) has decreased by -51.70% and quarterly revenue (Sales) growth year over year stands at -6.70%. Gross margin is detected at 35.80% that represents the percent of total sales revenue that the company retains after direct cost of goods sold. Net profit margin (ttm) is 3.80% while return on equity (ttm) is 6.50%.

Recent Developments:

2020-05-09 – On Semiconductor Reports First Quarter 2020 Results.
2020-04-09 – On Semiconductor Says As Part Of Co’s Ongoing Efforts To Reduce Costs, Determined To Implement Certain Employee Terminations During H1 2020.
2020-03-06 – ON Semiconductor Updates First Quarter 2020 Revenue Outlook.
2020-02-03 – On Semiconductor Reports Q4 Earnings Per Share $0.14.
2019-12-03 – ON Semiconductor Corporation Presents at Nasdaq 41st London Investor Conference, Dec-03-2019 08:45 AM.

AbbVie Inc. (ABBV), a Drug Manufacturers—General business, was a bullish stock in the prior market session. AbbVie Inc. (ABBV) shares opened at $90.00 and closed the day at $90.46 with positive move of +2.91%. The increase move in AbbVie Inc. (ABBV) beat the move in the S&P 500 for the day which losed -2.05% in prior market session.

AbbVie Inc. (ABBV) is focused on the Drug Manufacturers—General sector. This market sector has seen some action from day traders in recent months. Bullish day traders of AbbVie Inc. (ABBV) will be looking for positive upcoming earnings whereas bearish day traders of AbbVie Inc. (ABBV) will be looking for negative earnings. The last time AbbVie Inc. (ABBV) had an earnings surprise was on Qtr Ending 03/20 when they reported $2.42 compared to an estimate of $2.27 which was a difference of $+0.15 resulting in a change of +6.61%. Current earnings estimates are to be released for Current Qtr 06/2020 on AbbVie Inc. (ABBV) and out of 4 Wall Street estimates the average is saying $2.19. The high estimate is saying $2.27 whereas the low estimate is saying $2.11 and the prior year AbbVie Inc. (ABBV) announced earnings at $2.26 a growth rate est. (year over year) of -3.10%.

The market performance of AbbVie Inc. (ABBV) has varied recently. Year to date AbbVie Inc. (ABBV)’s shares are down -0.72%. Over the past 12 weeks AbbVie Inc. (ABBV) is down -6.54% and over the last 4 weeks AbbVie Inc. (ABBV) is up 9.46%. AbbVie Inc. (ABBV) current income statement shows revenue (ttm) of $34.06B. Gross Profit is $25.83B. This puts the current EBITDA of AbbVie Inc. (ABBV) at $16.02B.

Wall street day traders might also notice recent changes to stock analyst estimates for AbbVie Inc. (ABBV). The stock is trading with an RSI (relative strength index) of 64.66 indicating AbbVie Inc. (ABBV) is neither overbought nor oversold. Technically, ABBV’s short term support levels are around $14.51, $13.98 and $13.01 on the downside. ABBVs short term resistance levels are $23.50, $22.70 and $22.24 on the upside. The market cap of AbbVie Inc. (ABBV) is $159.421B and institutions hold 76.76% of the stock. The outstanding share count stands at 1.48B while the short float (shares short) stands at 5.74%.

Research indicates that these financial estimate changes look to be directly correlated with short-term shares prices. The day traders can look to capitalize on the basis of ranking. Based on technical analysis, ABBV has short term rating of Bullish (0.25), Intermediate rating of Neutral (0.02) and the long-term rating of Bullish (0.31) giving it an overall rating of Neutral (0.19).

The EPS growth this year on AbbVie Inc. (ABBV) is increased 42.30% and is expected to increase 7.41% next year. However, quarterly earnings (EPS) growth year over year on AbbVie Inc. (ABBV) has increased by 22.50% and quarterly revenue (Sales) growth year over year stands at 10.10%. Gross margin is detected at 77.10% that represents the percent of total sales revenue that the company retains after direct cost of goods sold. Net profit margin (ttm) is 25.20% while return on equity (ttm) is -103.70%.

Recent Developments:

2020-05-08 – Abbvie Says Borrowed $3.0 Bln Under Term Loan Credit Agreement.
2020-05-06 – Abbvie Says Allergan CEO Brent Saunders Has Elected Not To Join Abbvie Board.
2020-05-01 – Abbvie Says Saw Modest Impact To New Patient Starts For Some Drugs Due To COVID-19 Restrictions: Q1 Conf Call.
2020-05-01 – Abbvie Reports Qtrly Adjusted Earnings Per Share $2.42.
2020-04-21 – FDA approves ibrutinib plus rituximab for chronic lymphocytic leukemia.